Tests ECMO support for heart attack patients in cardiogenic shock
Tests ECMO heart-lung support in adults with heart attack and severe shock.
Plain-language title generated from the registry record
Registry title: Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Hopital Pitie-SalpetriereParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT04184635
- Record updated
- 14 January 2025
- Original description
Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days).Read full original descriptionShow less
Assessment of ECMO in Acute Myocardial Infarction With Non-reversible Cardiogenic Shock to Halt Organ Failure and Reduce Mortality (ANCHOR)
Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days).
An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of the experimental treatment arm.
Inclusion: Cardiogenic shock complicating acute myocardial infarction (STEMI or NSTEMI); Revascularization by PCI for acute myocardial infarction has been performed or is planned in the following 60 minutes; Systolic blood pressure <90 mmHg for >30 min or catecholamine support required to maintain systolic blood pressure >90 mmHg; Signs of pulmonary congestion; Signs of impaired organ perfusion with at least one of the following:; Altered mental status OR cold, clammy skin and extremities OR oliguria with urine output <30 ml/h OR serum lactate >2.0 mmol/l.
Exclusion: Surgical revascularization for AMI (CABG) planned or already performed prior to randomization; Severe peripheral artery disease or previous aortic or ilio-femoral surgery precluding ECMO and IABP insertion; Other severe concomitant disease with limited life expectancy < 1 year; No intrinsic heart activity; Age <18 years; Pregnancy; Onset of shock >24 Hours; Shock of other cause (hypovolemic, anaphylactic or vagal shock); Shock due to massive pulmonary embolism; Resuscitation >30 minutes; Patient moribund on the day of randomization or SAPS II >90; Cerebral deficit with fixed dilated pupils or Irreversible neurological pathology; Mechanical infarction complication (massive mitral regurgitation, pericardium drainage required, septal ventricular defect); Aortic regurgitation > II; Proven heparin-induced thrombocytopenia; ECMO device not immediately available.